Clinical Trial

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II trial to evaluate the efficacy and safety of immune checkpoint inhibitors in combination with axitinib for previously treated advanced collecting duct carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-08.
Status change: Not Yet Recruiting → Recruiting 2024-11-21
Trial Details
NCT Number NCT06211114
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Collecting Duct Carcinoma
Enrollment 30 participants
Start Date 2024-02-09
Primary Completion 2026-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2024-11-26